Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon 中 contact icon menu icon
Medicilon Logo
|
search icon close search icon 中 contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 20 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research
Biology Research
Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
Active Pharmaceutical Ingredients
Pharmaceutical preparation
Analytical Method Development and Quality Control
CMC Filings
Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics
Drug Safety Evaluation
DMPK
Bioanalysis
IND Filings
01 One-stop Integrated Services
Liposome Drug Development
Drug Discovery
Pharmaceutical Research
Preclinical Research
Botanical Drug Preclinical R&D
02 Innovative Drug Services
ADC
PROTAC
mRNA Vaccine
Cellular Immunotherapies
Nucleic Acid Drug
Peptide Drug Conjugate (PDC)
Antibody
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection
Metabolite Identification (MetID)
Drug Forming Research
Flow Cytometry Technology
SEND Format Conversion
Flow Sorting
NanoString nCounter Detection
Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
IO Pharmacodynamic Model
Inflammatory and Immune Diseases
Rodent Cerebrovascular Disease
05 Advanced Preparation R&D
Inhalation drug
Ophthalmic drug
Skin Topical Preparation
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service
GLP-1 New Drug R&D Service
KRAS-targeted Drugs R&D Service
CAREERS
Talent Development
Campus Recruitment
Recruitment
Campus Recruitment
Campus Recruitment
Recruitment
Recruitment
News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2024-07-22Medicilon Events
The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together
On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.
Learn more
2024-07-22Medicilon Events
5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"
Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.
Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsFeatured Stories

Featured Stories

Hot information：
Top 10 Global CDMO Enterprises| The Meaning of IND, NDA and ANDA| Top 10 Global Clinical Research Organizations in 2021
Oct 15,2020
The Biological Analysis of Bispecific Atibody
With the development of bispecific antibody technology, bispecific antibody now presents a good development prospect. When major companies are deploying bi-antibody product research and development, they also need to pay attention to the detection and analysis of bi-antibody. Points to note and consider. Dr. Zhang Dengji, Director of Pharmaceutical Analysis Department of Medicilon Biotechnology, broughtRead more
More
The Biological Analysis of Bispecific Atibody
Oct 14,2020
Drug absorption, distribution, metabolism and excretion (pharmacokinetics)
Pharmacokinetics (PK), also known as pharmacokinetics, is a discipline that studies the process of drugs in the body, including the changes in the absorption, distribution, metabolism and excretion of drugs and their metabolites over time, and applied kinetics A quantitative description of this process by principles and mathematical processing methods. Pharmacokinetics is a discipline thatRead more
More
Drug absorption, distribution, metabolism and excretion (pharmacokinetics)
Oct 14,2020
High-throughput ADME research in the new drug discovery phase
In the past ten years, the cycle of drug discovery and development has become longer and longer, and the cost of testing has increased. In Western countries, it takes 10 to 15 years to develop and market a new compound entity, and it costs more than US$800 million. Of the 10,000 new compound entities, 10Read more
More
High-throughput ADME research in the new drug discovery phase
Oct 13,2020
Oncolytic virus and CAR-T open a new way to overcome the problem of solid tumors
Due to the combination of tumor and CAR-T immunotherapy, the amazing results produced are exciting. Medicilon followed closely with international companies in tumor models, especially in the field of immune tumor animal model evaluation systems, and introduced internationally advanced PET-CT imaging systems, radiotherapy radiation systems, IVIS small animal imaging systems, multi-channel flow cytometry analyzers, etc.Read more
More
Oncolytic virus and CAR-T open a new way to overcome the problem of solid tumors
Oct 10,2020
NAM: The nemesis of glaucoma struck, helping patients stay away from the “thief” of vision
Glaucoma is the leading cause of irreversible blindness worldwide. This disease causes vision loss when the optic nerve and retinal cells are lost. The etiology of the disease is complex, with a wide range of risk factors. Age, race, family history, myopia, cardiovascular disease, diabetes, abnormal blood rheology, etc. are all risk factors for glaucoma.Read more
More
NAM: The nemesis of glaucoma struck, helping patients stay away from the “thief” of vision
Oct 09,2020
PROTAC is first showing its edge, SD-36 has excellent anti-tumor effect
On November 11, the team of Chinese-American Wang Shaomeng published a paper titled "A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo” in the scientific journal Cancer Cell, which immediately stirred up thousands of people. Layers of waves have brought PROTAC technology back to people's sight. Shanghai Medicilon Biopharmaceutical Co.,Read more
More
PROTAC is first showing its edge, SD-36 has excellent anti-tumor effect
Oct 09,2020
LYTAC was born, fighting side-by-side with PROTAC to target non-medicable targets
The advent of PROTAC The advent of PROTAC has brought solutions to targets that traditional small-molecule drugs cannot be made into. After 2017, PROTAC technology has developed rapidly, from the laboratory to the industrial world, starting from Harvard University, Yale University, Arvinas, C4, Kymera Therapeutics have been established to specialize in PROTAC technical drug research,Read more
More
LYTAC was born, fighting side-by-side with PROTAC to target non-medicable targets
Oct 09,2020
Will vitamin D become a new hope for the prevention and treatment of COVID-19?
The rapid spread of COVID-19 is a public health emergency that has attracted international attention. The clinical situation of COVID-19 is still not fully understood, but it is obviously related to respiratory symptoms, and in some cases it can induce acute multiple organ failure. Respiratory distress syndrome (ARDS), especially in elderly patients with a historyRead more
More
Will vitamin D become a new hope for the prevention and treatment of COVID-19?
Sep 30,2020
Science Sub-Journal: A new model can predict the injectability of microparticle formulations
Particulate preparation refers to a solid, liquid, semi-solid or gaseous pharmaceutical preparation composed of particles with a certain particle size (micron or nanometer) made by a certain dispersion and embedding technology with a suitable carrier (generally a biodegradable material) It has excellent properties such as improving the stability of the drug, reducing adverse drug reactions,Read more
More
Science Sub-Journal: A new model can predict the injectability of microparticle formulations
Sep 29,2020
[Nature] New treatment plan for non-small cell lung cancer: targeted degradation of EGFR
Lung cancer is one of the most common malignant tumors in the world, and it has become the first cause of death from malignant tumors in the urban population of our country. Non-small cell lung cancer (NSCLC) includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Compared with small cell carcinoma, cancer cells grow andRead more
More
[Nature] New treatment plan for non-small cell lung cancer: targeted degradation of EGFR
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->